In 1985, IBSA (Institut Biochimique SA) was a small company in Lugano on the brink of bankruptcy. Today, 40 years later, the company celebrates the anniversary of its acquisition by its current CEO and President, Arturo Licenziati, who has led the business with a key philosophy: “Drugs in the best form”.

The year 2025 marks an important year for the IBSA Group (Institut Biochimique SA), which celebrates a double anniversary: 40 years of leadership by its CEO and President Arturo Licenziati, and 80 years since the creation of the IBSA name. These milestones coincide with another significant event: the 90^th birthday of President Licenziati, who today – April 3, 2025 – celebrates this major occasion.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250327550789/en/

To mark the company’s 40^th anniversary, IBSA has decided to grant all employees worldwide a day off on August 19, the date when Arturo Licenziati first stepped into IBSA.

“This is just a symbolic gesture to express my gratitude for the commitment, dedication and passion of our People, who are the driving force behind our growth. A growth that is not just about business, but also – and above all – about the ability to implement development and work models that place People at the centre of our philosophy and our activities”, said Licenziati.

Indeed, it was on August 19, 1985, that Licenziati took over the management of the Ticino-based company, founded in Lugano in 1945, redefining its vision and strategy. At that time, IBSA had just 40 employees and a turnover of 5 million Swiss francs. However, by the end of the 1980s – in just 5 years – the company had radically transformed, tripling its revenue.

The history of IBSA is the story of a company that evolved from a small pharmaceutical laboratory in the Swiss Canton Ticino into a multinational corporation. What many people saw as an impossible mission, President Licenziati embraced as a challenge to be won, with the aim of forging a new path, focused on innovation and the ability to respond to people’s actual needs.

“Small companies can only grow if they can adapt quickly to sectors that large pharmaceutical companies often overlook”, added Licenziati. “Over the years, we have transformed an idea –producing “drugs in the best form” – into a concrete and successful project, focusing on targeted research that meets the everyday needs of doctors and patients. We have always been a forward-looking company, ready to go beyond and willing to explore new, uncharted paths”.

Since the 1990s, IBSA has embarked on a global expansion, first in Europe and then worldwide. Today the company has 20 subsidiaries across Europe, China and the United States, and distributes its products in over 90 countries across 5 continents, with more than 2,300 employees between headquarters, subsidiaries and production sites.

About IBSA

IBSA (Institut Biochimique SA) is a Swiss multinational pharmaceutical company with 20 subsidiaries in Europe, China and the United States. Its products are distributed in over 90 countries and its research and development activity focuses on 10 therapeutic areas. In 2025, IBSA celebrates the 40^th anniversary of its acquisition by current President and CEO Arturo Licenziati, who transformed the company into a multinational that employs over 2,300 people worldwide. IBSA’s growth and development can be attributed to the ability to innovate by perfecting already known molecules, as well as to the desire to look to the future in a responsible and transparent way, thanks to the dedication and dynamism of its people.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250327550789/en/

Chérine Gurtner, Senior Consultant
cherine.gurtner@furrerhugi.ch

Tags

More Like This

After Three Successful Years With the IBSA Class40 and Skipper Alberto Bona, IBSA’s Sports Project Comes to an End

The Six Winning Projects of the 12th Edition of the IBSA Foundation Fellowships have been Awarded and the 2025 Call is Now Open

Hansa Biopharma publishes 2024 Annual and Sustainability Reports

From the surface to the deep structure of the face: IBSA Derma presents the new frontier of adipose tissue restoration in response to aging

Hansa Biopharma publishes 2023 Annual and Sustainability Reports

Alberto Bona on Board the Class40 IBSA Finishes the Transat Jacques Vabre in Third Place

HAS Healthcare Advanced Synthesis SA acquires Cerbios-Pharma SA to create leading international Group in the CDMO sector, backed by 65 Equity Partners

Unither Pharmaceuticals celebrates 30 years of innovation and expertise